Republic of Moldova
Tuberculosis profile
| High MDR-TB burden |
Population  2013 3.5 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.48 (0.45–0.5) 14 (13–14)
Mortality (HIV+TB only) 0.081 (0.063–0.1) 2.3 (1.8–2.9)
Prevalence  (includes HIV+TB) 7.9 (4–13) 226 (113–375)
Incidence  (includes HIV+TB) 5.5 (5–6.3) 159 (142–180)
Incidence (HIV+TB only) 0.34 (0.3–0.4) 9.8 (8.5–11)
Case detection, all forms (%) 81 (71–91)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 24 (21–26) 62 (59–65)
MDR-TB cases among notified pulmonary
TB cases
770 (700–850) 880 (840–930)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 1 865   542
Pulmonary, clinically diagnosed 1 403   309
Extrapulmonary 336   30
       
Total new and relapse 4 485    
Previously treated, excluding relapses 566    
Total cases notified 5 051    
Among 4 485 new and relapse cases:
134 (3%) cases aged under 15 years; male:female ratio: 2.6
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 1 610 (86%) 996 (69%) 2 620
Laboratory-confirmed RR-/MDR-TB cases     1 054
Patients started on MDR-TB treatment     931
TB/HIV 2013 Number (%)
TB patients with known HIV status 4 085 (81)
HIV-positive TB patients 250 (6)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART) 165 (66)
HIV-positive people screened for TB 3 332  
HIV-positive people provided with IPT    
Treatment success rate (%)
New and relapse cases registered in 2012 76
Previously treated cases, excluding relapse, registered in 2012 39
HIV-positive TB cases, all types, registered in 2012 47
RR-/MDR-TB cases started on second-line treatment in 2011 54
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 1.4
Culture (per 5 million population) 4.9
Drug susceptibility testing (per 5 million population) 4.9
Sites performing Xpert MTB/RIF 28
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2014  
National TB programme budget (US$ millions) 33
% Funded domestically 12%
% Funded internationally 21%
% Unfunded 67%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-08-04 Data: www.who.int/tb/data